Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4

Liver International

Volumn 34, Issue 6, 2014, Pages 890-895

  Ragheb, Mostafa M ^a   Nemr, Nader A ^a   Kishk, Rania M ^a   Mandour, Mohamed F ^a   Abdou, Mohamed M ^a   Matsuura, Kentaro ^b   Watanabe, Tsunamasa ^b   Tanaka, Yasuhito ^b  

^a Suez Canal University Faculty of Medicine   (Egypt)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Genotype 4; HCV; IL28B; rs12979860; rs8099917; SVR

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; INTERLEUKIN 28B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; VIRUS RNA;

ADULT; AGED; ALLELE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; MAJOR CLINICAL STUDY; MALE; NON VIROLOGICAL RESPONSE; PREDICTION; REAL TIME POLYMERASE CHAIN REACTION; RS12979860 GENE; RS8099917 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGICAL RESPONSE; TRANSIENT VIROLOGICAL RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIROLOGICAL RESPONSE; VIRUS GENE; BLOOD; CHI SQUARE DISTRIBUTION; DRUG COMBINATION; DRUG EFFECTS; GENE FREQUENCY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROZYGOTE; IMMUNOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; RISK; TIME; VIRUS LOAD; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; GENE FREQUENCY; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROZYGOTE; HUMANS; INDIVIDUALIZED MEDICINE; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT SELECTION; PHARMACOGENETICS; PHENOTYPE; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84902547461     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12321     Document Type: Article

References (31)

1. World Health Organization. Hepatitis C. Wkly Epidemiol Rec 1997; 72: 65-9.
2. Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 2008; 47: 1371-83.
3. El-Zanaty F, Way A. Egypt Demographic and Health Survey 2008. Egyptian: Ministry of Health. Cairo: El-Zanaty and Associates and Macro International, 2009; 251-2.
4. Miller FD, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci USA 2010; 107: 14757-62.
5. Fattovich G, Pantalena M, Zagni I, et al.; European Concerted Action on Viral Hepatitis (EUROHEP). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002; 97: 2886-95.
6. Brady B, Siebert U, Sroczynski G, et al. Pegylated Interferon Combined with Ribavirin for Chronic Hepatitis C Virus Infection: An Economic Evaluation [Technology report no 82]. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health (CADTH), 2007; 1-55.
7. Manns MP, McHutchison JG, Gordon SC, et al. Peg interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
8. Fried MW, Shiffman ML, Reddy KR, et al. Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
9. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006; 131: 1040-8.
10. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
11. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
12. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
13. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
14. Stättermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011; 9: 344-50.e2.
15. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-14.
16. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-45.
17. Khattab M, Eslam M, Sharwae MA, et al. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010; 105: 1970-7.
18. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
19. Tanaka Y, Nishida N, Sugiyama M, Tokunaga K, Mizokami M. lambda-Interferons and the single nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. Hepatol Res 2010; 40: 449-60.
20. Sharafi H, Pouryasin A, Alavian SM, et al. Development and validation of a simple, rapid and inexpensive PCR-RFLP method for genotyping of common IL28B polymorphisms: a useful pharmacogenetic tool for prediction of hepatitis C treatment response. Hepat Mon 2012; 12: 190-5.
21. Hendy O, El Moneam E, Al shafie E, et al. Role of IL28B gene polymorphisms in response to the standard of care treatment in Egyptian patients with chronic HCV genotype 4. Life Sci J, 2011; 8: 908-15.
22. Derbala M, Rizk N, Shebl F, et al. Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis. World J Gastroenterol 2012; 18: 7003-8.
23. El-Awady MK, Mostafa L, Tabll AA, et al. Association of IL28B SNP with progression of Egyptian HCV genotype 4 patients to end stage liver disease. Hepat Mon 2012; 12: 271-7.
24. Kurbanov F, Abdel-Hamid M, Latanich R, et al. Genetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort. Infect Dis 2011; 204: 1391-4.
25. Asselah T. Genetic polymorphism and response to treatment in chronic hepatitis C: the future of personalized medicine. J Hepatol 2010; 52: 452-4.
26. De Nicola S, Aghemo A, Rumi MG, et al. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. J Hepatol 2012; 55: 336-42.
27. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-9.e18. 4.
28. Liao XW, Ling Y, Li XH, et al. Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir Ther 2011; 16: 141-7.
29. Fischer J, Böhm S, Scholz M, et al. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 2012; 55: 1700-10.
30. Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, García-Álvarez M, Resino S. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med 2013; 11: 6.
31. Ito K, Higami K, Masaki N, et al. The rs8099917 polymorphism, when determined by a suitable genotyping method is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J Clin Microbiol 2011; 49: 1853-60.